Breast Cancer | Topics

Trastuzumab, Pertuzumab, and Docetaxel Treatment Comparable With T-DM1 in ErbB2+ Breast Cancer
July 21, 2021

Treatment with trastuzumab, pertuzumab, and docetaxel appears to yield similar efficacy to trastuzumab emtansine in patients with ErbB2-positive breast cancer.

FDA Grants Trilaciclib Plus Chemotherapy Fast Track Designation for Locally Advanced or Metastatic TNBC
July 20, 2021

The combination of trilaciclib plus chemotherapy has been granted a fast track designation by the FDA for the treatment of locally advanced metastatic triple-negative breast cancer.

Athenex Discusses Deficiencies of Oral Paclitaxel Plus Encequidar for Metastatic Breast Cancer in FDA Type A Meeting
July 07, 2021

The FDA supported Athenex to continue developing oral paclitaxel and encequidar for patients with metastatic breast cancer.